Skip Navigation



Rheumatology Advance Access published online on November 23, 2004
Rheumatology, doi:10.1093/rheumatology/keh487
Rheumatology © British Society for Rheumatology 2004; all rights reserved
This Article
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Rheumatology First Quarter 2005 Quiz
Right arrow All Versions of this Article:
44/3/274    most recent
keh487v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Takehara, K.
Right arrow Articles by Sato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takehara, K.
Right arrow Articles by Sato, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received May 27, 2004
Accepted October 19, 2004

Review

Localized scleroderma is an autoimmune disorder

K. Takehara 1* and S. Sato 1

1 Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

* To whom correspondence should be addressed.
K. Takehara, E-mail: takehara{at}med.kanazawa-u.ac.jp


  Abstract

Objectives. There have been many studies suggesting that localized scleroderma has a strong autoimmune background, although the lesions are usually limited to the skin and subcutaneous tissue. Here we summarize previous data on the autoimmunity of localized scleroderma, mostly published in the last two decades, because there has not been a review paper summarizing autoimmunity in this disorder.

Methods. We classified the previous reports into three categories: antinuclear antibodies; cytokine and soluble receptors; and cell adhesion molecules and cell surface molecules. In each category, we introduce the important investigations.

Results. High frequencies of antinuclear antibodies, detected by the indirect immunofluorescence method using cultured cells, are confirmed by many groups. The major autoantigens have been revealed to be histones. Recently, anti-topoisomerase II {alpha} antibody has been found to be detected highly frequently in localized scleroderma, while anti-topoisomerase I antibody, which is highly specific for systemic sclerosis, has not been detected in any case of localized scleroderma. In other studies, elevated serum cytokines and cell adhesion molecules suggest the immunoactivation of localized scleroderma.

Conclusions. Many previous studies conclude that localized scleroderma involves autoimmune abnormalities and is one of the organ-specific autoimmune disorders targeting mainly skin, although the types of autoimmune abnormality are different from systemic sclerosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
M. Horger, G. Fierlbeck, J. Kuemmerle-Deschner, N. Tzaribachev, M. Wehrmann, C. D. Claussen, and J. Fritz
MRI Findings in Deep and Generalized Morphea (Localized Scleroderma)
Am. J. Roentgenol., January 1, 2008; 190(1): 32 - 39.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Chen, S. Vodanovic-Jankovic, B. Johnson, M. Keller, R. Komorowski, and W. R. Drobyski
Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease
Blood, November 15, 2007; 110(10): 3804 - 3813.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.